Physician Perspectives 2017: Use of ustekinumab in IBD
- GDHC001SP
- Pages: 68
- February 2018
- Total Views:1126
- Region : Global
- GlobalData
- Market Research Report

Details
Physician Perspectives 2017: Use of ustekinumab in IBD
Summary
This Physician Perspectives survey focuses on the use of ustekinumab in IBD.
UST appears to be the preferred non-TNF biologic for treatment of moderate-to-severe Crohn's disease, most frequently prescribed after the failure of one or two anti-TNFs (most often IFX & ADA), and before VDZ.
73% of physicians reported having had high expectations of UST's efficacy, and 58% stated that these expectations had been met, while 12% stated that they had not been met.
Majority of physicians expected UST to be somewhat effective or effective to treat UC patients with left-sided UC, non-acute, steroid dependent UC, extensive UC, ulcerative proctitis, acute severe colitis, and to treat patients with a high BMI.
The report includes following topics-
- Current clinical use of UST
- UST safety & efficacy
- UST patient monitoring
- Treatment response to UST
- UST treatment strategies
- Future use in UC.
Scope
- Sociable Pharma conducted an online survey in Q4 2017, with 100 specialist gastroenterologists
- Physicians interviewed were from 5EU and US countries
- This report contains the findings from the survey, together with analysis, as well as an overview of the methodology used, and responder demographics.
Reasons to buy
- Qualitative insight from 100 high-prescribing specialists in IBD
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of emerging trends on management of IBD
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Table Of Content
Scope
Table of contents
Executive Summary
Methodology
Survey Results
Demographics
Appendix
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Ustekinumab, Crohn's disease, ulcerative colitis
Companies
Janssen
Takeda
AbbVie
Company Profile
Company Profile Title
Physician Perspectives 2017: Use of ustekinumab in IBD
Summary
This Physician Perspectives survey focuses on the use of ustekinumab in IBD.
UST appears to be the preferred non-TNF biologic for treatment of moderate-to-severe Crohn's disease, most frequently prescribed after the failure of one or two anti-TNFs (most often IFX & ADA), and before VDZ.
73% of physicians reported having had high expectations of UST's efficacy, and 58% stated that these expectations had been met, while 12% stated that they had not been met.
Majority of physicians expected UST to be somewhat effective or effective to treat UC patients with left-sided UC, non-acute, steroid dependent UC, extensive UC, ulcerative proctitis, acute severe colitis, and to treat patients with a high BMI.
The report includes following topics-
- Current clinical use of UST
- UST safety & efficacy
- UST patient monitoring
- Treatment response to UST
- UST treatment strategies
- Future use in UC.
Scope
- Sociable Pharma conducted an online survey in Q4 2017, with 100 specialist gastroenterologists
- Physicians interviewed were from 5EU and US countries
- This report contains the findings from the survey, together with analysis, as well as an overview of the methodology used, and responder demographics.
Reasons to buy
- Qualitative insight from 100 high-prescribing specialists in IBD
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of emerging trends on management of IBD
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Scope
Table of contents
Executive Summary
Methodology
Survey Results
Demographics
Appendix
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Ustekinumab, Crohn's disease, ulcerative colitis
Companies
Janssen
Takeda
AbbVie